SCHEMBL13340959

SCHEMBL13340959

CCN1C(=O)C(C)(C)S(=O)(=O)c2cc(C(C)C)ccc21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 2/20 0.34
OPRD1 P41143 1/20 0.34
MAPT P10636 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
ALDH1A1 P00352 2/20 0.32
TSHR P16473 2/20 0.32
OPRM1 P35372 1/20 0.32
OPRL1 P41146 1/20 0.32
PDK1 Q15118 1/20 0.32
PDK2 Q15119 1/20 0.32
PDK3 Q15120 1/20 0.32
PDK4 Q16654 1/20 0.32
NR1H3 Q13133 1/20 0.32
KMT2A Q03164 2/20 0.31
ATAD2 Q6PL18 1/20 0.31
MEN1 O00255 1/20 0.31
CRHR1 P34998 2/20 0.31
HPGD P15428 1/20 0.31
GFER P55789 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13340958 0.81 NR1H3 (0.39) OPRK1OPRD1ALDH1A1TSHROPRM1
SCHEMBL16601582 0.81 ALDH1A1 (0.38) MAPTALDH1A1TSHRKMT2AATAD2
SCHEMBL13961732 0.80 CASP3 (0.33) ALDH1A1KMT2AATAD2MEN1PKM
SCHEMBL13340967 0.80 SLC9A1 (0.35) OPRK1OPRM1OPRL1PDK1PDK2
SCHEMBL13340916 0.75 SLC9A1 (0.39) OPRK1OPRD1MAPTALDH1A1KMT2A
SCHEMBL9976989 0.74 TSHR (0.34) OPRK1OPRD1MAPTRXFP1TSHR
SCHEMBL13340953 0.72 OPRK1 (0.34) OPRK1OPRD1MAPTALDH1A1TSHR
SCHEMBL13340814 0.70 ATAD2 (0.64) ALDH1A1PDK1PDK2PDK3PDK4
SCHEMBL13340907 0.69 KMT2A (0.36) OPRK1OPRD1ALDH1A1OPRM1OPRL1
SCHEMBL20353865 0.68 BRD4 (0.59) ALDH1A1ATAD2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ OPRK1 1685/4885OPRD1 3050/4885MAPT 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.